Company: IXHL
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001213900-25-092837
Chunk: 179

Company: Incannex Healthcare Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 1
Chunk 179
---
 clinical and preclinical data and launch their product earlier than might otherwise
be the case. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish
the value of our patents or narrow the scope of our patent protection. The laws of international countries may not protect our rights
to the same extent as the laws of the United States, and these international laws may also be subject to change. Publications of discoveries
in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions
are typically not published until 18 months after filing or in some cases not at all. Therefore, we cannot be certain that we or our past,
current or future collaboration partners or licensors were the first to make the inventions claimed in our owned or licensed patents or
pending patent applications, or that we or our past, current or future collaboration partners or licensors were the first to file for
patent protection of such inventions.

72

Obtaining and maintaining our patent protection depends on compliance
with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent
protection could be reduced or eliminated for non-compliance with these requirements.

Periodic maintenance fees, renewal fees, annuity
fees and various other governmental fees on patents and applications are required to be paid to the USPTO and other governmental patent
agencies outside of the United States in several stages over the lifetime of the patents and applications. The USPTO and various corresponding
governmental patent agencies outside of the United States require compliance with a number of procedural, documentary, fee payment and
other similar provisions during the patent application process and after a patent has issued. There are situations in which non-compliance
can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the
relevant jurisdiction.

We may become involved in lawsuits to protect and defend our
patents or other intellectual property, which could be expensive, time consuming and unsuccessful.

Competitors may infringe our patents or other intellectual
property, and we may inadvertently infringe the patent or intellectual property of others. To counter infringement or unauthorized use,
we may be required to file claims, and any related litigation and/or prosecution of such claims can be expensive and time consuming. Any
claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe
their intellectual property. In addition, in a patent